COMMUNIQUÉS West-GlobeNewswire

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
10/05/2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
10/05/2024
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical [...]
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10/05/2024
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of [...]
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
10/05/2024
The FDA Assigned Goal Date is October 29, 2024 TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today [...]
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
10/05/2024
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Ocugen to Present at May 2024 Investor Conferences
10/05/2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
10/05/2024
GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on [...]
Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT
10/05/2024
- Data show that AXV-101 halts photoreceptor and outer nuclear retinal layer (ONL) degeneration in a dose-dependent manner - - Company to initiate clinical studies in 1H 2025 to treat blindness and progress AXV-101 [...]
Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
10/05/2024
Management to host conference call and webcast at 8:30am ET PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial [...]
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
10/05/2024
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 [...]
Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
10/05/2024
– Significant advancements in engineering neutralizing antibody (NAb) evasion properties into receptor-targeted capsids, including novel TfR1-binding capsids, demonstrate increased opportunities to treat AAV [...]
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
10/05/2024
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD [...]
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
10/05/2024
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with novel mechanisms of [...]
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
10/05/2024
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real- [...]
Humacyte First Quarter 2024 Financial Results and Business Update
10/05/2024
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from [...]
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
10/05/2024
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates [...]
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
10/05/2024
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a [...]
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
10/05/2024
Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7% , net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82 Delivered record [...]
Le TAR-200 en monothérapie montre un taux de réponse complète supérieur à 80 pour cent chez les patients atteints d’un cancer de la vessie n’infiltrant pas le muscle à haut risque
10/05/2024
Les nouvelles données issues de l’étude de Phase IIb SunRISe-1 montrent l’obtention rapide d’une réponse complète (RC), 98 pour cent des patients ayant présenté une RC dans les 12 semaines 1 Le TAR-200 permet d’obtenir [...]

Pages